The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna shares were up 5.9% on Wednesday, while Pfizer was up 1%. GSK’s American ...

Moderna announced Tuesday its RSV vaccine for older adults was about 84% effective at preventing severe disease and the company plans to ask the FDA for approval in 2023. ABC News.

According to a press release, Moderna’s RSV vaccine was 83.7% effective in preventing at least two symptoms associated with RSV in older adults (age 60 and up) in a phase-three clinical trial.

Moderna’s mRNA-Based RSV Vaccine Just Passed a Major Test. 3 minute read. By Alice Park. January 18, 2023 11:10 AM EST. M oderna has become a well-known name thanks to its highly effective COVID ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Moderna announced positive results Tuesday from its phase 3 trial of an RSV vaccine for older adults, revealing plans to submit the vaccine for regulatory approval, which includes review by the US ...

Moderna has finally succeeded in landing its second product approval from the U.S. Food and Drug Administration after its Covid-19 vaccine.

And while 2023 brought the development of a monoclonal antibody for infants, a type of passive immunization that provides short-term protection from RSV, there has yet to be an actual RSV vaccine for ...

Moderna is also working on an RSV vaccine of its own. The shot is currently in Phase 3 trials, setting the company up for a commercial launch in 2024 assuming it gains regulatory approval.

July 5 (UPI) --Moderna has submitted its RSV vaccine for people 60 and older regulatory approval in the United States and elsewhere in the world, the company said."We are proud to announce these ...

Moderna regains rights to adult RSV vaccine program from Merck . Start of Phase 1 dosing for mRNA-1345, Moderna’s vaccine candidate against RSV Moderna has consolidated all rights to its ...

On January 17, Moderna announced that data from a late-stage clinical trial for the company’s experimental messenger RNA (mRNA) vaccine for respiratory syncytial virus (RSV) was 83.7 percent ...